Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

Kura gets $45M from Kyowa Kirin; Pliant cuts 45% staff; AstraZeneca's Breztri succeeds in asthma trials; Otsuka ends ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology.

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

HHS rolled out a new $500 million initiative to develop universal vaccines for 'pandemic-prone' viruses such as influenza and ...

FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two ...

Bristol Myers Squibb closing viral vector site in Libertyville, IL, shifting production to Devens, MA; affects workers from ...

Moderna tried to assuage investors Thursday that enhanced scrutiny of its vaccines in the US wouldn’t hamper its progress.

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...